Mursla Bio presented data at The Liver Meeting suggesting that its EvoLiver diagnostic test can spot liver cancer among cirrhotic patients with 86% early-stage sensitivity and 88% specificity

blonca9
Nov 18, 2024
1 min read

CEO Pierre Arsѐne describes how the test analyses hepatocyte extracellular vesicles, and how he believes this result surpasses the current standards of testing such as ultrasound and alpha-fetoprotein testing.

Recent Posts

See All

With a phase 3 trial for its PRAME cell therapy underway and a data update coming up at ASCO, Immatics is pushing to be a leader in TCR based cell therapies and T-cell engagers

Mosaic Therapeutics, which uses advanced computational methods and next-generation cancer models to design novel combination therapies, licensed an ERK1/2 and MDM2 inhibitor from Astex Pharmaceuticals

Cambridge, UK based Epitopia is helping Merck (MSD) discover tumor associated antigens from the non-coding regions of the genome using its CryptoMap platform

Mursla Bio presented data at The Liver Meeting suggesting that its EvoLiver diagnostic test can spot liver cancer among cirrhotic patients with 86% early-stage sensitivity and 88% specificity

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight